Pathophysiology of spondyloarthritis

Current Rheumatology Reports

Volumn 13, Issue 5, 2011, Pages 416-420

  Ronneberger, Monika ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Ankylosing spondylitis; Bone formation; Enthesitis; HLA B27; Osteitis; Pathophysiology; Spondyloarthritis; Structural damage; Syndesmophytes

Indexed keywords

HLA B27 ANTIGEN;

ANKYLOSIS; BONE MARROW; ENTHESITIS; ERAP1 GENE; GENE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HLA B27 GENE; HUMAN; IL23R GENE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROORGANISM; OSSIFICATION; PATHOPHYSIOLOGY; REVIEW; SPINE; SPONDYLOARTHROPATHY;

GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; INFLAMMATION; OSTEOGENESIS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 80755139507     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0202-x     Document Type: Review

References (37)

1. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973, 1(7809):904-7.
2. Schlosstein L, Terasaki PI, Bluestone R, et al. High association of an HL-A antigen, W 27, with ankylosing spondylitis. N Engl J Med. 1973, 288(14):704-6.
3. Lau CS, Burgos-Vargas R, Louthrenoo W, et al. Features of spondyloarthritis around the world. Rheum Dis Clin North Am. 1998, 24(4):753-70. (Pubitemid 28524022)
4. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol. 1995, 7(4):263-9.
5. Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 1997, 49(2):116-23. (Pubitemid 27084693)
6. Erratum in: Tissue Antigens 1997 Sep; 50(3):315.
7. Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987;329:512.
8. Madden DR, Gorga JC, Strominger JL, et al. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell. 1992, 70(6):1035-48.
9. Kim TH, Uhm WS, Inman RD. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol. 2005, 17(4):400-5. (Pubitemid 41058398)
10. Khan MH. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol. 2000;12:235.
11. D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol. 1995, 25(11):3199-201.
12. Wucherpfennig KW Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype. J Exp Med. 2004, 199(2):151-4. (Pubitemid 38129696)
13. Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum. 2005, 52(3):892-901. (Pubitemid 40365113)
14. Fiorillo MT, Maragno M, Butler R, et al. CD8 (+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest. 2000, 106(1):47-53. (Pubitemid 30437239)
15. Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol. 1997;27:133119.
16. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010, 42(2):123-7. Epub 2010 Jan 10.
17. • Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007 Nov; 39(11):1329-37. ARTS1 and IL23R are two new loci related to AS and, moreover IL23R probably is a common susceptibility factor for the "seronegative' disease. (Pubitemid 350041542)
18. Cawley MI, Chalmers TM, Kellgren JH, et al. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis. 1972;31:345.
19. Appel H, Rudwaleit M, Sieper J. Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Nat Clin Pract Rheumatol. 2008, 4(11):578.
20. Rauner M, Stupphann D, Haas M, et al. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J Rheumatol. 2009, 36(1):120-6.
21. Maksymowych WP MRI in ankylosing spondylitis. Curr Opin Rheumatol. 2005;17:413.
22. Oostveen J, Prevo R, de Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol. 1999;26:1953.
23. Schett G, Stolina M, Dwyer D, et al. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum. 2009;60:2644-54.
24. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11:221.
25. Benjamin M, Toumi H, Suzuki D, et al. Evidence for a distinctive pattern of bone formation in enthesophytes. Ann Rheum Dis. 2008;14.
26. Samoto H, Shimizu E, Matsuda-Honjyo Y, et al. Prostaglandin E2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. J Biol Chem. 2003, 278(31):28659.
27. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002, 109(11):1405-15. (Pubitemid 34596166)
28. Rosen V BMP and BMP inhibitors in bone. Ann N YAcad Sci. 2006;1068:19.
29. Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006;54:1736-46. (Pubitemid 43877923)
30. Baron R, Rawadi G Minireview: targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-43. (Pubitemid 46984775)
31. • Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156-63. Inhibiting Dickkopf-1 in the Wnt pathway results information of osteophytes in a murine model.
32. Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2009 Mar. 26.
33. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009, 60(11):3257.
34. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signalling inhibitor. J Biol Chem. 2005;280:26770-5. (Pubitemid 41040710)
35. •• van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063. Two years of infliximab therapy do not prevent progression of spinal damage in patients with AS.
36. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324.
37. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009, 11:R127.